DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[A clinical study of cyclopyroxolamine versus clotrimazole in the treatment of mycotic vulvovaginitis]

Author(s): Giannoni M, Pollastro M, Jacobellis M

Affiliation(s): Consultorio Familiare U.S.L. n. 8, Genova Ponente.

Publication date & source: 1990-07, Minerva Med., 81(7-8):555-9.

Publication type: Clinical Trial; Randomized Controlled Trial

The therapeutic efficacy and tolerability of the antifungal agent ciclopiroxolamine have been verified with a double-blind study versus clotrimazole in 46 patients affected by vulvovaginal candidiasis. The patients of the first group (23) have been treated with ciclopiroxolamine globules, one 100 mg globule nightly for six days; the second group (23 patients) received clotrimazole vaginal tablets, one 200 mg tablet nightly for six days. Ciclopiroxolamine treatment showed an equivalent effectiveness to that of clotrimazole both on signs and symptoms and on vaginal smear culture. No local or systemic adverse reaction was observed.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017